ChargePoint CCXO Sells $13K Shares Amidst EBITDA Loss by Mark Eisenberg 22.06.2024 Jagdeep Singh, ChargePoint CCO, sells 9,389 shares at $1.3971 each to cover taxes, holding 886,364 shares, indicating confidence in company’s ...
System1 CEO Michael Blend Sells $1.08M in Shares by Mark Eisenberg 22.06.2024 System1 CEO Michael Blend sells $1.08M in shares, transferring to CEE Holdings Trust. Key financial and governance changes outlined.
Lone Star Trust Sells System1 Shares for $7.16M by Mark Eisenberg 22.06.2024 Lone Star Friends Trust sells 4.775M shares of System1, Inc. for $7.16M in a major transaction. Future strategies focus on ...
Sunrun Director Jurich Sells $605k in Company Stock by Mark Eisenberg 22.06.2024 Sunrun Director Lynn Jurich sells $605k in stock; company remains a key player in residential solar amid financial challenges and ...
EPA to Review Texas Oversight of Wastewater Disposal Wells by Mark Eisenberg 22.06.2024 EPA to review Texas oversight of wastewater disposal wells amid concerns of blowouts and seismic activity, driven by environmental groups' ...
Veris Director Invests $143K in Company Stock by Mark Eisenberg 22.06.2024 Nori Gerardo Lietz buys 10,000 shares in Veris Residential, Inc., reflecting confidence in the REIT's future amidst key strategy shifts ...
Fidelity Seeds Ethereum ETF with $4.7M, Lowest Fee Yet by John Darbie 22.06.2024 "Fidelity seeds Ethereum ETF with $4.7M, marking a significant step before July launch. Other major players like BlackRock join competition."
Cryptocurrency Price Predictions: Ethereum, Polygon, XRP – June 21 by John Darbie 22.06.2024 "Ethereum dips 1% amid SEC updates, Polygon sees rising locked assets, and XRP struggles below $0.50 due to CEO's legal ...
Under Armour Settles $434M Class Action Lawsuit by Mark Eisenberg 22.06.2024 Under Armour to pay $434M in class action settlement over misleading disclosures, maintaining separate Chair and CEO roles for three ...
Lilly’s Zepbound Resolves Sleep Apnea in 52% of Patients by Mark Eisenberg 22.06.2024 Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...